Absence of HBV reactivation in patients with resolved HBV infection following DAA therapy for hepatitis C : a 1-year follow-up study
- Background: Patients with chronic hepatitis C virus (HCV) infection and active or previous hepatitis B virus (HBV) are at risk of HBV reactivation (HBV-R) during direct-acting antiviral (DAA) therapy. Recent reports suggest that HBV-R may even occur several months after completion of DAA therapy. The aim of this study was to assess the risk of HBV-R in patients with resolved HBV after successful DAA therapy during long-term follow-up (FU). Methods: Among 848 patients treated for chronic HCV, all patients with resolved HBV and long-term FU data were eligible for inclusion. Patients were HBV DNA/hepatitis B surface antigen (HBsAg)–negative at the end of therapy (EOT) and were followed for up to 52 weeks thereafter. Patients underwent regular alanine transaminase (ALT) testing, and additional HBV DNA/HBsAg testing was performed at FU week 12, end of FU, and in case of an ALT increase above the upper limit of normal (>ULN). Results: A total of 108 patients were followed up for a mean (range) of 41.5 (24–52) weeks after EOT. None of the patients experienced reverse HBsAg seroconversion or reappearance of HBV DNA. One patient received a liver transplantation; 1 patient was diagnosed with de novo hepatocellular carcinoma, and 2 patients died. Eighteen patients (16.7%) had increased ALT levels (grade 0/1). Of those, the majority were male (72.2%) and significantly more patients had cirrhosis (66.7% vs 36.2%, P = .015) or received ribavirin as part of their treatment regimen (86.7% vs 46.8%, P = .041). None of these were associated with HBV-R. Conclusions: Our results indicate that the risk of HBV-R in patients with resolved HBV treated with DAAs for HCV is low during long-term follow-up.
Author: | Marcus Maximilian MückeORCiDGND, Victoria Therese MückeORCiDGND, Kai-Henrik PeifferORCiDGND, Christoph SarrazinGND, Stefan ZeuzemORCiDGND, Annemarie BergerGND, Johannes VermehrenGND |
---|---|
URN: | urn:nbn:de:hebis:30:3-488603 |
DOI: | https://doi.org/10.1093/ofid/ofy340 |
ISSN: | 2328-8957 |
Pubmed Id: | https://pubmed.ncbi.nlm.nih.gov/30648130 |
Parent Title (English): | Open Forum Infectious Diseases |
Publisher: | Oxford University Press |
Place of publication: | Oxford |
Document Type: | Article |
Language: | English |
Year of Completion: | 2018 |
Date of first Publication: | 2018/12/15 |
Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
Release Date: | 2019/02/07 |
Tag: | HBV reactivation; HCV treatment; direct-acting antivirals; hepatitis B virus; hepatitis C virus; long-term follow-up |
Volume: | 6 |
Issue: | 1, ofy340 |
Page Number: | 5 |
First Page: | 1 |
Last Page: | 5 |
Note: | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
HeBIS-PPN: | 446489549 |
Institutes: | Medizin / Medizin |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Sammlungen: | Universitätspublikationen |
Open-Access-Publikationsfonds: | Medizin |
Licence (English): | Creative Commons - Namensnennung-Nicht kommerziell 4.0 |